[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340520-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340520-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","interpretable-deep-cross-networks-unveiled-common-signatures-of-dysregulated-epitranscriptomes-across-12-cancer-types","Interpretable deep cross networks unveiled common signatures of dysregulated epitranscriptomes across 12 cancer types","","Cancer shows diverse molecular drivers, yet shared mechanisms across tumor types at the epitranscriptome level remain unclear. This study analyzes 167 m6A epitranscriptome profiles from 12 cancer types and their matched normal tissues. Interpretable deep cross networks were trained to distinguish normal–cancer m6A contexts using sequences plus curated genomic knowledge. Cross-cancer testing reveals shared signatures; a pan-cancer model captures patterns absent in single cancers, linked to RNA hybridization and aberrant splicing, supporting RNA-methylation–based therapeutics.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/interpretable-deep-cross-networks-unveiled-common-signatures-of-dysregulated-epitranscriptomes-across-12-cancer-types/340520/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/interpretable-deep-cross-networks-unveiled-common-signatures-of-dysregulated-epitranscriptomes-across-12-cancer-types/340520.png","ImageObject",300,407,{"name":42,"@type":43},"Evangeline","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What biological layer does this study focus on in cancer?","Question",{"text":63,"@type":64},"It focuses on the epitranscriptome, specifically N6-methyladenosine (m6A) RNA methylation patterns across cancer types and normal tissues.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the modeling approach designed in the study?",{"text":68,"@type":64},"The work trains interpretable deep cross network models for each cancer type to distinguish normal versus cancer m6A contexts using both sequence information and curated genomic knowledge.",{"name":70,"@type":61,"acceptedAnswer":71},"What shared finding does the pan-cancer analysis reveal?",{"text":72,"@type":64},"The pan-cancer model identifies a common epitranscriptome signature shared across multiple cancer types, associated with RNA hybridization processes and aberrant splicing.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340520,1790241049,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Original Article  \nInterpretable deep cross networks unveiled common signatures of dysregulated epitranscriptomes across 12 cancer types  \nRong Xia, 1,3,4,8 Xiangyu Yin,3,7,8 Jiaming Huang,3 Kunqi Chen,5 Jiongming Ma,3 Zhen Wei,3,6 Jionglong Su,4 Neil Blake,7 Daniel J. Rigden,7 Jia Meng,2,3,7 and Bowen Song 1  \n1Department of Public Health, School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China; 2Institute of Biomedical Research, Regulatory Mechanism and Targeted Therapy for Liver Cancer Shiyan Key Laboratory, Hubei Provincial Clinical Research Center for Precise Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China; 3Department of Biological Sciences, School of Science, Suzhou Key Laboratory of Cancer Biology and Chronic Disease, Xi’an Jiaotong-Liverpool University, Suzhou 215123, China; 4School of AI and Advanced Computing, XJTLU Entrepreneur College (Taicang), Xi’an Jiaotong-Liverpool University, Suzhou, Jiangsu 215123, China; 5Key Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350004, China; 6Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, L7 8TX Liverpool, UK; 7Institute of Systems, Molecular and Integrative Biology, University of Liverpool, L7 8TX Liverpool, UK  \nCancer is a complex and multifaceted group of diseases characterized by uncontrolled cell growth that leads to the formation of malignant tumors. Recent studies suggest that N6-methyladenosine (m6A) RNA methylation plays pivotal roles in cancer pathology by inﬂuencing various cellular processes. However, the degree to which these mechanisms are shared across different cancer types remains unclear. In this study, we analyze an expansive array of 167 m6A epitranscriptome proﬁles covering 12 distinct cancer types and their originating normal tissues. We trained 12 distinct, cancer type-speciﬁc interpretable deep cross network models, which successfully distinguish between speciﬁc pairs of normal and cancer m6A contexts using integrated information from both the sequences and curated genomic knowledge. Interestingly, cross-cancer type testing indicated the existence of shared genomic patterns across various cancers at the epitranscriptome level. A pan-cancer model was subsequently developed to identify these shared patterns that could not be observed in a single cancer type. Our analysis uncovered, for the ﬁrst time, a common epitranscriptome signature shared across multiple cancer types, particularly associated with RNA hybridization process and aberrant splicing. This highlights the importance of a comprehensive understanding of the pan-cancer epitranscriptome and holding potential implications in the development of RNA methylation-based therapeutics for various cancers.  \nINTRODUCTION  \nOur understanding of cancer biology has been continuously broadening through systematic studies that focus on both genetic and epigenetic alterations in oncogenes, shedding light on the intricate molecular mechanisms that drive tumorigenesis.1,2 Accumulating evidence has indicated a strong effect of RNA methylation on tumor initiation and cancer progression,3–7 mostly for the well-studied  \nN6-methyladenosine (m6A) methylome. In human disease, m6A dysregulation has been reported to play an essential role in tumor proliferation, migration, and invasion across different cancer types,8,9 including breast cancer,10, 11 lung cancer, 12 bladder tumors, 13, 14 and liver cancer.15, 16 However, the function and mechanism of m6Amethylation in regulating many tumor processes still remain poorly characterized, especially on the key question of whether multiple cancer types share commonalities at the epitranscriptomic layer.  \nPrevious pan-cancer analysis has successfully identiﬁed shared posttranslational modiﬁcations patterns of protein regulation, such aspan-cancer patterns of changes ","cbCaia9oKT2tKJVt","https://ap.wps.com/l/cbCaia9oKT2tKJVt","pdf",3865181,14,"English","# Introduction\n## Pan-cancer epitranscriptome disturbance and motivation\n## Background on RNA methylation (m6A) in cancer\n## Prior pan-cancer analyses and limitations\n## Study context and significance","[{\"question\":\"What biological layer does this study focus on in cancer?\",\"answer\":\"It focuses on the epitranscriptome, specifically N6-methyladenosine (m6A) RNA methylation patterns across cancer types and normal tissues.\"},{\"question\":\"How was the modeling approach designed in the study?\",\"answer\":\"The work trains interpretable deep cross network models for each cancer type to distinguish normal versus cancer m6A contexts using both sequence information and curated genomic knowledge.\"},{\"question\":\"What shared finding does the pan-cancer analysis reveal?\",\"answer\":\"The pan-cancer model identifies a common epitranscriptome signature shared across multiple cancer types, associated with RNA hybridization processes and aberrant splicing.\"}]","Interpretable deep cross networks unveiled common signatures of dysregulated epitranscriptomes across 12 cancer types | PDF",1790037053,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c4a9faf6588353786d21d296fcced2d.webp",983,1276,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15e09fbcdaf4f41bfc4d52b3c2c952da.webp",982,1275,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e76f7d85a88c27942c937b3e232ac6d.webp",981,1273,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cc4bd5369348d2f66a8e4e7c8bb1b67.webp",980,1272]